Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

ID
Name
02-22-161-060
Description
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Trial arms
Trial start
2020-03-01
Estimated PCD
2024-09-30
Trial end
2025-06-13
Status
Recruiting
Treatment
Antihistamine
Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with
Arms:
Patients with chronic treatment with antihistamines or amantadine
Other names:
Antihistamine as crhonic treatment and COVID19 infection.
Amantadine
Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine
Arms:
Patients with chronic treatment with antihistamines or amantadine
Other names:
Amantadine as chronic treatment and COVID19 infection.
Size
170000
Primary endpoint
Hospital Admissions.
from march 2020.
Eligibility criteria
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine - Exclusion Criteria: None -
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 170000, 'type': 'ESTIMATED'}}
Updated at
2024-04-26

1 organization

2 products

1 indication

Organization
Consorci Sanitari de Terrassa
Product
Antihistamine
Indication
COVID-19
Product
Amantadine